Arvinas Inc
ARVN7.900USD
+0.670+9.27%
交易中 （美東）報價延遲15分鐘
543.53M總市值
虧損本益比TTM
關於 Arvinas Inc 公司
Arvinas, Inc. 是一家臨牀階段的生物技術公司。該公司通過其 PROteolysis Targeting Chimera (PROTAC) 蛋白質降解劑平臺，率先開發蛋白質降解療法，旨在利用人體的天然蛋白質處理系統選擇性高效地降解和去除致病蛋白質。該公司正在通過臨牀開發項目推進多種研究藥物，包括 vepdegestrant、ARV-393 和 ARV-102。Vepdegestrant 是一種口服生物可利用的 PROTAC 蛋白質降解劑，旨在靶向和降解 ER，用於治療局部晚期或轉移性 ER+/HER2- 乳腺癌患者。該公司正在與輝瑞共同開發 vepdegestrant。ARV-393 是一種口服生物可利用的 PROTAC，旨在降解 BCL6，這是一種轉錄抑制因子和正常 B 細胞成熟和分化過程的關鍵調節劑。ARV-102 正在開發中，用於治療神經退行性疾病。
公司簡介
公司代碼ARVN
公司名稱Arvinas Inc
上市日期- -
成立日期- -
CEO- -
員工數量- -
證券類型Ordinary Share
年結日- -
公司地址- -
城市- -
上市交易所NASDAQ Global Select Consolidated
國家- -
郵編- -
電話- -
網址- -
公司代碼ARVN
上市日期- -
成立日期- -
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
986.41K
+13.94%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
110.02K
-7.30%
Dr. Ian Taylor, Ph.D.
Dr. Ian Taylor, Ph.D.
President - Research and Development
President - Research and Development
105.53K
+12.35%
Dr. Angela Cacace
Dr. Angela Cacace
Chief Scientific Officer
Chief Scientific Officer
96.74K
+86.56%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
5.90K
--
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
5.90K
--
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
5.90K
--
Mr. Jared Morris Freedberg
Mr. Jared Morris Freedberg
General Counsel
General Counsel
--
--
Dr. Laurie Smaldone Alsup, M.D.
Dr. Laurie Smaldone Alsup, M.D.
Independent Director
Independent Director
--
--
John Young ,
John Young ,
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
986.41K
+13.94%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
110.02K
-7.30%
Dr. Ian Taylor, Ph.D.
Dr. Ian Taylor, Ph.D.
President - Research and Development
President - Research and Development
105.53K
+12.35%
Dr. Angela Cacace
Dr. Angela Cacace
Chief Scientific Officer
Chief Scientific Officer
96.74K
+86.56%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
5.90K
--
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
5.90K
--
收入明細
FY2024
FY2023
暫無數據
地區USD
名稱
營收
佔比
United States
263.40M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 2月28日 週五
更新時間: 2月28日 週五
持股股東
股東類型
持股股東
股東統計
佔比
The Vanguard Group, Inc.
11.46%
EcoR1 Capital, LLC
9.22%
BlackRock Institutional Trust Company, N.A.
7.24%
T. Rowe Price Associates, Inc.
5.51%
Citadel Advisors LLC
4.77%
Other
61.81%
持股股東
股東統計
佔比
The Vanguard Group, Inc.
11.46%
EcoR1 Capital, LLC
9.22%
BlackRock Institutional Trust Company, N.A.
7.24%
T. Rowe Price Associates, Inc.
5.51%
Citadel Advisors LLC
4.77%
Other
61.81%
股東類型
股東統計
佔比
Investment Advisor/Hedge Fund
40.57%
Investment Advisor
35.44%
Hedge Fund
18.71%
Corporation
4.76%
Venture Capital
3.17%
Research Firm
2.67%
Individual Investor
2.42%
Sovereign Wealth Fund
1.70%
Private Equity
1.52%
機構持股
更新時間: 3月3日 週一
更新時間: 3月3日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
493
81.65M
117.98%
-2.97M
2024Q4
505
80.31M
116.78%
-4.24M
2024Q3
496
79.95M
116.50%
-140.10K
2024Q2
489
78.26M
114.11%
+1.71M
2024Q1
494
75.44M
110.48%
+3.48M
2023Q4
497
68.16M
100.81%
+12.55M
2023Q3
472
52.04M
94.71%
-3.94M
2023Q2
473
53.77M
100.76%
-3.55M
2023Q1
475
55.60M
104.22%
-4.17M
2022Q4
484
56.43M
106.14%
-6.62M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
7.05M
10.26%
+56.56K
+0.81%
Dec 31, 2024
EcoR1 Capital, LLC
6.73M
9.78%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.29M
7.69%
+152.31K
+2.97%
Dec 31, 2024
T. Rowe Price Associates, Inc.
4.02M
5.85%
+289.37K
+7.75%
Dec 31, 2024
Citadel Advisors LLC
3.48M
5.06%
+407.46K
+13.26%
Jan 30, 2025
Pfizer Inc
3.46M
5.03%
--
--
Dec 31, 2024
RTW Investments L.P.
3.33M
4.85%
+551.98K
+19.84%
Dec 31, 2024
Bellevue Asset Management AG
2.39M
3.47%
+3.00K
+0.13%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
2.21M
3.21%
+2.21M
--
Dec 31, 2024
UBS Financial Services, Inc.
2.01M
2.93%
+1.54M
+329.49%
Dec 31, 2024
查看更多
持股ETF
更新時間: 9 小時前
更新時間: 9 小時前
機構名稱
佔比
SPDR S&P Pharmaceuticals ETF
1.93%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.35%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
Range Cancer Immunotherapy ETF
0.49%
Tema Oncology ETF
0.39%
Federated Hermes MDT Small Cap Core ETF
0.19%
iShares U.S. Pharmaceuticals ETF
0.18%
Zacks Small/Mid Cap ETF
0.16%
JPMorgan Fundamental Data Science Small Core ETF
0.13%
Tema Neuroscience and Mental Health ETF
0.13%
查看更多
SPDR S&P Pharmaceuticals ETF
佔比1.93%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比1.35%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.86%
Range Cancer Immunotherapy ETF
佔比0.49%
Tema Oncology ETF
佔比0.39%
Federated Hermes MDT Small Cap Core ETF
佔比0.19%
iShares U.S. Pharmaceuticals ETF
佔比0.18%
Zacks Small/Mid Cap ETF
佔比0.16%
JPMorgan Fundamental Data Science Small Core ETF
佔比0.13%
Tema Neuroscience and Mental Health ETF
佔比0.13%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據